Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$176.64 USD

176.64
9,476,916

+1.92 (1.10%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $177.00 +0.36 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (80 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

J&J Signs Another Collaboration to Develop Coronavirus Vaccine

J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.

Zacks Equity Research

Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates

Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.

Zacks Equity Research

Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates

Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.

Zacks Equity Research

Emergent (EBS) Begins Development of Treatments for COVID-19

Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.

Kinjel Shah headshot

3 Small Biotechs Provide Coronavirus Drug Development Updates

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

Zacks Equity Research

Mallinckrodt Up on New York's Support for Opioid Settlement

Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.

Zacks Equity Research

Emergent BioSolutions Collaborates for Coronavirus Vaccine

Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.

Zacks Equity Research

AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure

AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment

Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Alphabet, Johnson & Johnson, Morgan Stanley and Bank of America

The Zacks Analyst Blog Highlights: Microsoft, Alphabet, Johnson & Johnson, Morgan Stanley and Bank of America

Zacks Equity Research

Millennials Are Inclined Toward ESG: Here's Why

ESG investment has carved a niche in stock markets and millennials are the ones driving its rapid growth.

Kinjel Shah headshot

Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Moves -1.02%: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $142.01, moving -1.02% from the previous trading session.

Zacks Equity Research

J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe

Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Kinjel Shah headshot

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Zacks Equity Research

Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?

Style Box ETF report for IWX

Kinjel Shah headshot

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

Zacks Equity Research

AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.

Mark Vickery headshot

Top Stock Reports for Eli Lilly, Union Pacific & Lockheed

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Union Pacific (UNP) and Lockheed Martin (LMT).

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Zacks Equity Research

Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4

Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Zacks Equity Research

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $143.68, marking a -0.67% move from the previous day.